Lauriane Lemelle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lauriane Lemelle has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
9 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
9 shared publications - Alexander Gregory Weil
Brain and Development Research Axis, Sainte-Justine Research Center, Montreal, Canada
9 shared publications - Alvaro Lassaletta
Hospital Infantil Universitario Niño Jesús
9 shared publications - An Van Damme
Department of Pediatric Hematology Oncology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
9 shared publications - Ana Aguilar-Bonilla
Department of Pediatric Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA 02115, USA
9 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- Open Access
- 3 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 561-572
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
- 3 December 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (3) , 561-572
Open AccessClinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Purpose: Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients. Experimental Design: We conducted an international retrospective cohort study of patients with TRK fusion–driven central nervous system tumors. Results: A total of 119 patients were identified. The median age at the time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG; 57.1%) followed by low-grade glioma (LGG; 27.7%). Pediatric patients had a better prognosis, with a median overall survival of 185.5 months compared with 24.8 months in adults (P < 0.0001). Patients with LGG also had a better outcome when compared with HGG (P = 0.0012). The objective response was 68.8% with larotrectinib compared with 38.1% for nontargeted treatment. Conclusions: Children with LGG had a favorable outcome compared with adult glioma and HGG. TRK inhibitors seem to improve tumor control.
- Open Access
- 22 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1) , e6782
Targeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study
Introduction: Introduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based on adult studies. Currently, the International Society of Pediatric Oncology–Renal Tumor Study Group (SIOP‐RTSG) 2016 UMBRELLA protocol recommends sunitinib for metastatic or unresectable RCC.Methods: This retrospective study describes the effects of tyrosine kinase inhibitors (TKI), anti‐programmed cell death 1 (PD‐(L)1) monoclonal antibodies, and immunotherapeutic regimens in advanced‐stage and relapsed pediatric RCC.Results: Of the 31 identified patients (0–18 years) with histologically proven RCC, 3/31 presented with TNM stage I/II, 8/31 with TNM stage III, and 20/31 with TNM stage IV at diagnosis. The majority were diagnosed with translocation type RCC (MiT‐RCC) (21/31) and the remaining patients mainly presented with papillary or clear‐cell RCC. Treatment in a neoadjuvant or adjuvant setting, or upon relapse or progression, included mono‐ or combination therapy with a large variety of drugs, illustrating center specific choices in most patients. Sunitinib was often administered as first choice and predominantly resulted in stable disease (53%). Other frequently used drugs included axitinib, cabozantinib, sorafenib, and nivolumab; however, no treatment seemed more promising than sunitinib. Overall, 15/31 patients died of disease, 12/31 are alive with active disease, and only four patients had a complete response. The sample size and heterogeneity of this cohort only allowed descriptive statistical analysis.Conclusion: This study provides an overview of a unique series of clinical and treatment characteristics of pediatric patients with RCC treated with targeted therapies.
- 22 December 2023
- Published by Wiley in Cancer Medicine
- Vol. 13 (1) , e6782
Open AccessTargeted therapies in children with renal cell carcinoma (RCC): An International Society of Pediatric Oncology—Renal Tumor Study Group (SIOP‐RTSG)‐related retrospective descriptive study
Introduction: Introduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based on adult studies. Currently, the International Society of Pediatric Oncology–Renal Tumor Study Group (SIOP‐RTSG) 2016 UMBRELLA protocol recommends sunitinib for metastatic or unresectable RCC.Methods: This retrospective study describes the effects of tyrosine kinase inhibitors (TKI), anti‐programmed cell death 1 (PD‐(L)1) monoclonal antibodies, and immunotherapeutic regimens in advanced‐stage and relapsed pediatric RCC.Results: Of the 31 identified patients (0–18 years) with histologically proven RCC, 3/31 presented with TNM stage I/II, 8/31 with TNM stage III, and 20/31 with TNM stage IV at diagnosis. The majority were diagnosed with translocation type RCC (MiT‐RCC) (21/31) and the remaining patients mainly presented with papillary or clear‐cell RCC. Treatment in a neoadjuvant or adjuvant setting, or upon relapse or progression, included mono‐ or combination therapy with a large variety of drugs, illustrating center specific choices in most patients. Sunitinib was often administered as first choice and predominantly resulted in stable disease (53%). Other frequently used drugs included axitinib, cabozantinib, sorafenib, and nivolumab; however, no treatment seemed more promising than sunitinib. Overall, 15/31 patients died of disease, 12/31 are alive with active disease, and only four patients had a complete response. The sample size and heterogeneity of this cohort only allowed descriptive statistical analysis.Conclusion: This study provides an overview of a unique series of clinical and treatment characteristics of pediatric patients with RCC treated with targeted therapies.